Review of teriflunomide and its potential in the treatment of multiple sclerosis

Clemens Warnke, Gerd Meyer Zu Hörste, Hans Peter Hartung, Olaf Stüve, Bernd C. Kieseier

Research output: Contribution to journalReview articlepeer-review

80 Scopus citations


In the light of new cases of progressive multifocal leukoencephalopathy and induced autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming disease-modifying immunosuppressant drugs with a highly specific mode of action such as natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less severely affected MS patients are a major focus of drug development. These agents are currently investigated in phase III clinical trials and some of them are characterized by a favorable safety profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options for patients with MS are discussed.

Original languageEnglish (US)
Pages (from-to)333-340
Number of pages8
JournalNeuropsychiatric Disease and Treatment
Issue number1
StatePublished - 2009


  • Immunosuppressant
  • Multiple sclerosis
  • Oral drugs
  • Teriflunomide

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry


Dive into the research topics of 'Review of teriflunomide and its potential in the treatment of multiple sclerosis'. Together they form a unique fingerprint.

Cite this